Drug Delivery to the Brain: Challenges and Progress
Drug Delivery to the Brain: Challenges and Progress
批准号:
10540503
负责人:
Thale Cross Jarvis
金额:
$1.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2023-08-31
关键词:
AcademiaAddressAlzheimer&aposs DiseaseAreaBiochemicalBiologyBloodBlood - brain barrier anatomyBlood VesselsBrainCareer ChoiceCentral Nervous System AgentsCentral Nervous System DiseasesCerebrospinal FluidCerebrovascular systemClinical ResearchCollaborationsColoradoDevelopmentDiseaseDrug Delivery SystemsEducational workshopEngineeringEventFosteringFutureGeneticGoalsHealthIndustryIntentionInternationalKnowledgeLearningMedicalMethodologyMethodsNeuraxisNeurosciencesOligonucleotidesOralOutcomeParkinson DiseasePatientsPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhysiologyPostdoctoral FellowProteinsResearchResearch PersonnelScienceScientistStudentsTechnologyTimeTissuesWorkbench to bedsidecareerclinical practicedesigndiversity and inclusiondrug developmentgene therapyimprovedinnovationlearning networkmeetingsmultidisciplinaryneurosurgerynext generationnovelnovel strategiesposterspre-clinical researchresearch studysmall moleculesymposium
中文摘要
摘要
请求支持Keystone研讨会,题为药物输送到大脑:挑战和
进展,由Robert Thorne博士和Reina Bendayan博士组织。会议将在#年举行
2023年1月26日至29日,科罗拉多州布雷肯里奇。
本次Keystone研讨会旨在解决对创新、新技术的迫切科学需求
中枢神经系统(CNS)给药途径。事实上,目前缺乏治疗疾病的药物
阿尔茨海默氏症、帕金森氏症和其他中枢神经系统疾病的治疗属于最重要的未获满足的
我们这个时代的健康需求。我们能够有效地利用蛋白质、寡核苷酸和
治疗中枢神经系统疾病的基因疗法受到大脑功能通常不足的严重限制。
全身用药或集中用药后的暴露。甚至许多口服的小剂量
分子受到大脑暴露的限制。造成这些限制的主要原因包括
存在于关键中枢神经系统界面的物理和生化屏障,包括
脑血管系统,血液和脑脊液之间的其他特殊屏障,以及进一步
阻碍脑脊液与中枢神经系统组织间药物交换的障碍。中枢神经系统药物释放研究
位于许多不同领域的十字路口,包括生理学、药理学、药剂学
科学、神经科学、神经外科、工程学、遗传学和血管生物学等。令人惊讶的是
到目前为止,很少有会议专门关注与CNS相关的多学科挑战
药物递送。这次研讨会的目标是:(一)汇聚国际专家和青年
来自多个研究领域的研究人员,目的是交流新思想和集思广益
解决现有的中枢神经系统药物递送挑战和(Ii)突出新的方法和视角
有可能改变中枢神经系统药物释放研究的进行方式,并最终改变
菲尔德。会议将包括一些简短的演讲,以整合最新的发展和新的
来自该领域的研究方向。
英文摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Drug Delivery to the Brain: Challenges and
Progress, organized by Drs. Robert Thorne and Reina Bendayan. The conference will be held in
Breckenridge, Colorado from January 26-39, 2023.
This Keystone Symposia conference is designed to address the urgent scientific need for innovative, new
approaches to central nervous system (CNS) drug delivery. Indeed, the current shortage of disease-modifying
treatments for Alzheimer’s, Parkinson’s and other CNS diseases represent among the most significant unmet
health needs of our time. Our ability to effectively tap into the vast potential that protein, oligonucleotide, and
gene therapies have for treating CNS disorders has been sharply limited by the typically insufficient brain
exposure that results after their systemic or central administration. Even many orally administered small
molecules suffer from brain exposure limitations. Among the primary reasons for these limitations are the
physical and biochemical barriers that exist at key CNS interfaces, including the blood-brain barrier at the level
of the cerebrovasculature, other specialized barriers between the blood and cerebrospinal fluid, and further
obstacles hindering drug exchange between cerebrospinal fluid and CNS tissue. CNS drug delivery research
lies at the crossroads between many different fields, including physiology, pharmacology, pharmaceutical
science, neuroscience, neurosurgery, engineering, genetics, and vascular biology, among others. Surprisingly
few conferences to date have focused exclusively on the multidisciplinary challenges associated with CNS
drug delivery. The goals of this symposium are (i) to bring together international experts and junior
investigators from multiple research fields for the purpose of exchanging new ideas and brainstorming novel
solutions to existing CNS drug delivery challenges and (ii) to highlight new methods and perspectives with the
potential to change how CNS drug delivery research studies are performed and, ultimately, to transform the
field. Sessions are to include a number of short talks chosen to integrate late-breaking developments and new
research directions from the field.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioenergetics in Health and Diseases
-
批准号:10609120
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Autophagy and Neurodegeneration: Mechanisms to Therapies
-
批准号:10608666
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Adipose Tissue: Energizing Good Fat
-
批准号:10609127
-
项目类别:
-
资助金额:$2.02万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Cancer Neoantigens, Vaccines and Viruses
-
批准号:10233861
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Small Regulatory RNAs: From Bench to Bedside
-
批准号:10462420
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Engineering Multi-Cellular Living Systems
-
批准号:10462913
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Gut-Brain Axis
-
批准号:10467819
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Malaria: Confronting Challenges From Drug Discovery to Treatment
-
批准号:10468493
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
The Human Microbiome: Ecology and Evolution
-
批准号:10391370
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics
-
批准号:10468419
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Progress in Vaccine Development for Infectious Diseases
-
批准号:10467880
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies
-
批准号:10462412
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neurocircuitry of Social Behavior
-
批准号:10540465
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Resolution of Inflammation
-
批准号:10469175
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Organoids as Tools for Fundamental Discovery and Translation
-
批准号:10469084
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Novel Approaches Against Emerging Antimicrobial Resistance
-
批准号:10391767
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Precision Genome Engineering
-
批准号:10391367
-
项目类别:
-
资助金额:$2.22万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neuronal Control of Appetite
-
批准号:10468571
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Innate Immunity: Complement and Beyond
-
批准号:10464340
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Humoral Immunity: From Regulation to Dysregulation
-
批准号:10469165
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
海外基金